Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium breve CCFM1067
- Development stage
- Preclinical
- Lead developer
- Jiangnan University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium breve CCFM1067 is a specific probiotic strain of the species *Bifidobacterium breve* that has been investigated for its neuroprotective effects via the microbiota-gut-brain axis (MGBA). In preclinical models of Parkinson's disease (PD), oral administration of CCFM1067 has demonstrated the ability to protect dopaminergic neurons, suppress neuroinflammation and glial cell hyperactivation, and alleviate oxidative stress. It works by modulating the intestinal microbiota—specifically reducing pathogenic bacteria like *Escherichia-Shigella* and increasing beneficial genera such as *Akkermansia*—and increasing the production of short-chain fatty acids (SCFAs) like acetate and butyrate. These actions help maintain the integrity of both the intestinal and blood-brain barriers, suggesting its potential as an oral supplement for the prevention or treatment of neurodegenerative conditions.
- Other names
- Bifidobacterium breve 1067
Beyond the preview
Go deeper on Bifidobacterium breve CCFM1067.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium breve CCFM1067.